(Reuters) – Antibody levels against the novel coronavirus rose and then held steady for up to four months in more than 90% of recovered COVID-19 patients in Iceland, according to a study published on Tuesday.
FILE PHOTO: A man wearing a protective face mask walks past an illustration of a virus outside a regional science centre, as the city and surrounding areas face local restrictions in an effort to avoid a local lockdown being forced upon the region, amid the coronavirus disease (COVID-19) outbreak, in Oldham, Britain August 3, 2020. REUTERS/Phil Noble/File Photo
In previous studies, antibody levels dropped sharply within a few months after COVID-19, raising questions about the duration of immunity that infection may provide.
The new finding may have implications for reinfection risks and vaccine durability, said Kari Stefansson, chief executive of deCode Genetics, which conducted the study.
To get a sense of how many people in Iceland had been infected with the new coronavirus and learn more about immune status after recovery, researchers measured antibody levels in more than 30,000 Icelanders.
Based on the results, they estimate that about 1% of the population had been infected. Of that group, 56% had received a confirmed diagnosis after a gold-standard PCR laboratory test. Another 14% had not been formally diagnosed but had quarantined after exposure to the virus. In the remaining 30%, the antibody tests led to discovery of prior infection.
Among the 1,215 people with an infection confirmed by PCR, 91% had antibody levels that rose during the first two months after diagnosis and then plateaued, researchers reported.
The results, published in The New England Journal of Medicine, focused on a homogeneous population from a single country, so the findings may not be the same in other parts of the world with diverse populations.
Still, the study shows how careful antibody tests can determine the true prevalence of infection, Stefansson said.
An editorial that accompanied the study cautioned that it is unclear if recovered patients’ antibodies will protect them from reinfection.
However, it suggested that antibody tests may be a cost-effective alternative to infection testing alone, and may work better in surveying populations as countries look to safely reopen their economies and schools.
Reporting by Vishwadha Chander in Bengaluru; editing by Nancy Lapid and Bill Berkrot